INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.
July 12 2023 - 8:00AM
INmune Bio, Inc. (NASDAQ: INMB) (the
“Company”), a clinical-stage immunology company focused on
developing treatments that harness the patient’s innate immune
system to fight disease has been invited to discuss drug
development strategies in aging and rejuvenation at
the 5th World Aging and Rejuvenation Conference in
Frankfurt, Germany on July 17, 2023.
Modern medicine has extended the average life span to more than
75 years old in the US.. An unintended consequence of this extended
life span is a decline in overall health in the latter years of
life. Health span, which refers to the period of life characterized
by good health, is currently at odds with life span due to the
prevalence of chronic diseases of aging. Chronic diseases of aging
affect virtually every organ system, including the heart, brain,
eyes, ears, bones, and skeletal muscles. Unfortunately, they
contribute to a diminished health span, resulting in shortened life
spans, increased elder care costs, and reduced quality of life.
Many of these chronic diseases of aging are the result of chronic
inflammation, leading the National Institute of Health to term it
"inflammaging." Inflammaging is characterized by a
persistent, low-grade inflammation that develops with advancing
age, independent of apparent infections, and potentially
exacerbates other age-related conditions.
Cognitive aging is one of the most prevalent chronic diseases
associated with advancing age. Almost all adults have a
gradual decline in cognitive function that becomes meaningful in
the mid 50s then accelerates after age 65. . It is
important to differentiate cognitive aging from Alzheimer’s disease
(AD). AD appears around the eighth decade of life, exhibits
more pronounced cognitive dysfunction and is characterized by
amyloid plaques. “Cognitive aging is a well-defined disease
that has not been the subject of extensive clinical study or
intervention,” said CJ Barnum, VP CNS Development at INmune Bio.
“We believe cognitive aging is driven by
neuroinflammation. INmune Bio has developed biomarkers
specifically designed to measure neuroinflammation in Early AD
patients, that are well-suited for studying cognitive aging.”
The study of inflammaging is still in its early stages, as
its cause is a culmination of genetic (ApoE4 gene), epigenetic
(diabetes, cardiovascular, autoimmunity), behavioral (obesity,
smoking, sedentary living, diet), environmental (pesticides,
pollution) and biologic (cellular senescence) factors.
Unfortunately, no treatments currently exist for inflammaging.”
“The field of aging research and drug development has many
challenges,” said RJ Tesi, MD, CEO of INmune Bio said.
“Conducting anti-aging clinical trials based on direct
measures of reduced aging is very difficult, if not impossible
due to the extensive length of the trials. Biomarkers and
surrogate endpoints of aging must be used in order to effectively
develop therapies to enhance health span.” The topic of the plenary
talk is a strategy to employ innovative neuroimaging biomarkers and
sensitive measures of cognitive function that were perfected in our
AD program to study cognitive aging. The literature supports
the hypothesis that chronic neuroinflammation is a driving factor
in cognitive aging. “Because of our experience in treating AD
patients with neuroinflammation, we know how to measure and treat
neuroinflammation with XPro,” said Dr. Tesi. “We believe the
insights gained from treating neuroinflammation in AD should be
applicable to the treatment of cognitive aging.”
The talk, entitled: “Using Enrichment Criteria for Clinical
Trials in Aging: Using Biomarkers of Peripheral Inflammation
to Predict Cognitive Dysfunction” will be
presented at 9AM CES on the 17th of July.
About INmune Bio, Inc.
INmune Bio
Inc. is a publicly traded (NASDAQ: INMB),
clinical-stage biotechnology company focused on developing
treatments that target the innate immune system to fight disease.
INmune Bio has two product platforms that are both in clinical
trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF)
product platform utilizes dominant-negative technology to
selectively neutralize soluble TNF, a key driver of innate immune
dysfunction and a mechanistic driver of many diseases. DN-TNF
product candidates are in clinical trials to determine if they can
treat cancer (INB03™), Early Alzheimer’s disease, and
treatment-resistant depression (XPro™). The Natural Killer Cell
Priming Platform includes INKmune™ developed to prime a patient’s
NK cells to eliminate minimal residual disease in patients with
cancer. INmune Bio’s product platforms utilize a precision medicine
approach for the treatment of a wide variety of hematologic and
solid tumor malignancies, and chronic inflammation. To learn more,
please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance
that any specific outcome will be achieved. Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of
1995. Any statements contained in this press release that do
not describe historical facts may constitute forward-looking
statements as that term is defined in the Private Securities
Litigation Reform Act of 1995. Any forward-looking statements
contained herein are based on current expectations but are subject
to a number of risks and uncertainties. Actual results and the
timing of certain events and circumstances may differ materially
from those described by the forward-looking statements as a result
of these risks and uncertainties. INB03™, XPro1595 (XPro™), and
INKmune™ are still in clinical trials or preparing to start
clinical trials and have not been approved by the US Food and Drug
Administration (FDA) or any regulatory body and there cannot be any
assurance that they will be approved by the FDA or any regulatory
body or that any specific results will be achieved. The factors
that could cause actual future results to differ materially from
current expectations include, but are not limited to, risks and
uncertainties relating to the Company’s ability to produce more
drug for clinical trials; the availability of substantial
additional funding for the Company to continue its operations and
to conduct research and development, clinical studies and future
product commercialization; and, the Company’s business, research,
product development, regulatory approval, marketing and
distribution plans and strategies. These and other factors are
identified and described in more detail in the Company’s filings
with the Securities and Exchange Commission, including the
Company’s Annual Report on Form 10-K, the Company’s Quarterly
Reports on Form 10-Q and the Company’s Current Reports on Form 8-K.
The Company assumes no obligation to update any forward-looking
statements in order to reflect any event or circumstance that may
arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720 info@inmunenbio.com
Investor Contact: Jason Nelson Core IR (516)
842-9614 Ext: 823
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
INmune Bio (NASDAQ:INMB)
Historical Stock Chart
From Apr 2023 to Apr 2024